Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation - PubMed (original) (raw)
Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation
M Kaleko et al. Mol Cell Biol. 1990 Feb.
Abstract
The human insulinlike growth factor I receptor was overexpressed in NIH 3T3 cells as well as human and rat primary fibroblast strains. The NIH 3T3 cells displayed a ligand-dependent, highly transformed phenotype. When exposed to insulinlike growth factor I or supraphysiologic levels of insulin, NIH 3T3 cells that expressed high levels of receptors formed aggregates in tissue culture dishes, colonies in soft agar, and tumors in nude mice. Expression of 1 million receptors per cell, a 40-fold increase above the base-line level, was required for anchorage-independent growth. Primary fibroblasts that expressed high levels of receptors displayed a ligand-dependent change in morphology and an increase in saturation density but did not acquire a fully transformed phenotype. The results demonstrate that when amplified, this ubiquitous growth factor receptor behaves like an oncogenic protein and is capable of promoting neoplastic growth in vivo.
Similar articles
- Constitutive phosphorylation of the receptor for insulinlike growth factor I in cells transformed by the src oncogene.
Kozma LM, Weber MJ. Kozma LM, et al. Mol Cell Biol. 1990 Jul;10(7):3626-34. doi: 10.1128/mcb.10.7.3626-3634.1990. Mol Cell Biol. 1990. PMID: 2162477 Free PMC article. - NIH 3T3 cells transfected with a yeast H(+)-ATPase have altered sensitivity to insulin, insulin growth factor-I, and platelet-derived growth factor-AA.
Peterson EP, Martinez GM, Martinez-Zaguilan R, Perona R, Gillies RJ. Peterson EP, et al. J Cell Physiol. 1994 Jun;159(3):551-60. doi: 10.1002/jcp.1041590319. J Cell Physiol. 1994. PMID: 8188769 - Modulation of insulinlike growth factor I binding to human fibroblast monolayer cultures by insulinlike growth factor carrier proteins released to the incubation media.
De Vroede MA, Tseng LY, Katsoyannis PG, Nissley SP, Rechler MM. De Vroede MA, et al. J Clin Invest. 1986 Feb;77(2):602-13. doi: 10.1172/JCI112343. J Clin Invest. 1986. PMID: 2418066 Free PMC article.
Cited by
- Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies.
Mahipal A, Shibata D, Siegel E, Springett G, Almhanna K, Fulp W, Williams-Elson I, Kim R. Mahipal A, et al. Invest New Drugs. 2015 Oct;33(5):1093-9. doi: 10.1007/s10637-015-0277-8. Epub 2015 Aug 16. Invest New Drugs. 2015. PMID: 26275531 Free PMC article. Clinical Trial. - Roles of insulinlike growth factor 1 (IGF-1) and the IGF-1 receptor in epidermal growth factor-stimulated growth of 3T3 cells.
Pietrzkowski Z, Sell C, Lammers R, Ullrich A, Baserga R. Pietrzkowski Z, et al. Mol Cell Biol. 1992 Sep;12(9):3883-9. doi: 10.1128/mcb.12.9.3883-3889.1992. Mol Cell Biol. 1992. PMID: 1324408 Free PMC article. - ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis.
Campbell CI, Petrik JJ, Moorehead RA. Campbell CI, et al. Mol Cancer. 2010 Sep 8;9:235. doi: 10.1186/1476-4598-9-235. Mol Cancer. 2010. PMID: 20825649 Free PMC article. - Growth Hormone/Insulin Growth Factor Axis in Sex Steroid Associated Disorders and Related Cancers.
Bleach R, Sherlock M, O'Reilly MW, McIlroy M. Bleach R, et al. Front Cell Dev Biol. 2021 Mar 18;9:630503. doi: 10.3389/fcell.2021.630503. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33816477 Free PMC article. Review.
References
- EMBO J. 1986 Oct;5(10):2503-12 - PubMed
- Proc Natl Acad Sci U S A. 1983 Mar;80(5):1228-31 - PubMed
- Nature. 1987 Feb 5-11;325(6104):549-52 - PubMed
- N Engl J Med. 1987 Apr 9;316(15):941-3 - PubMed
- Biochem Biophys Res Commun. 1987 Feb 27;143(1):199-205 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical